Interferons: mechanisms of action and clinical applications
- 1 November 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 15 (6) , 431-439
- https://doi.org/10.1097/00001622-200311000-00005
Abstract
Interferons are pleiotropic cytokines that exhibit important biologic activities, including antiviral, antitumor, and immunomodulatory effects. These cytokines have found important applications in clinical medicine, including the treatment of certain malignancies. The purpose of this review is to provide an update on basic and clinical research in the interferon field. Significant advances have recently occurred in the field of type I interferon signal transduction. It is well known that the interferons transduce signals via activation of multiple signaling cascades, involving Jak kinases, signal transducer and activator of transcription proteins, Map kinases, and IRS and Crk proteins. Recent evidence indicates that the p38 Map kinase pathway plays an important role in type I interferon signaling in malignant cells and that its function is required for type I interferon-dependent gene transcription and generation of the antiproliferative of type I interferons. In clinical oncology, interferon-α remains an active and useful agent in the treatment of several malignant disorders, and efforts are underway to improve its efficacy by using different schedules and combinations with other agents. This review summarizes the mechanisms of signal transduction of interferons and the emerging new concepts in this area. An update on the clinical applications of interferons in oncology is also provided, and potential translational applications, reflecting recent advances in the field, are discussed.Keywords
This publication has 108 references indexed in Scilit:
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Phase II trial of interferon‐α‐2a plus psolaren with ultraviolet light A in patients with cutaneous T‐cell lymphomaCancer, 2002
- The CrkL Adapter Protein Is Required for Type I Interferon-Dependent Gene Transcription and Activation of the Small G-Protein Rap1Biochemical and Biophysical Research Communications, 2002
- IFNα sensitizes ME‐180 human cervical cancer cells to TNFα‐induced apoptosis by inhibiting cytoprotective NF‐κB activationFEBS Letters, 2001
- Interferon-Dependent Activation of the Serine Kinase PI 3′-Kinase Requires Engagement of the IRS Pathway but Not the Stat PathwayBiochemical and Biophysical Research Communications, 2000
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- THE IFNγ RECEPTOR:A Paradigm for Cytokine Receptor SignalingAnnual Review of Immunology, 1997
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyNew England Journal of Medicine, 1990
- Interferon alfa-2a in the treatment of cutaneous T cell lymphomaJournal of the American Academy of Dermatology, 1989
- INTERFERONS AND THEIR ACTIONSAnnual Review of Biochemistry, 1987